Dr. Reddy's Laboratories (ADR) (RDY)
Produces generics, branded medicines, biosimilars, active ingredients, and consumer health products.
Something off on this page? Send us feedback.
Sells prescription generics, branded generics, biosimilars, active pharmaceutical ingredients, and over-the-counter products across the United States, India, Russia and the CIS, China, Brazil, and Europe. Global Generics supplies most revenue, supported by PSAI and newer consumer-health portfolios.
Produces active pharmaceutical ingredients, prescription generics, branded generics, biosimilars, and over-the-counter products. Global Generics is the economic center, while Pharmaceutical Services and Active Ingredients supplies APIs and intermediates and newer portfolios extend into nutrition and nicotine replacement.
Operates from Hyderabad across major markets including the United States, India, Russia and the CIS, China, Brazil, and Europe. Its model combines in-house pharmaceutical manufacturing with country-level branded portfolios and acquired products, reflecting an access-to-medicines purpose rooted in its 1984 API origin.
U.S. sales depend on FDA product approvals and sustained manufacturing compliance. Portfolio expansion also depends on integrating acquired prescription, branded, nutrition, and consumer-health products across different regulatory and commercial systems.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $851.9M · Total debt $752.8M · Total assets $6.02B · Shareholders' equity $4.01B
- Revenue
- $849.4M
- Operating income
- $31.1M
- Net income
- $46.7M
Reported in INR, converted at the latest exchange rate
HistoryDividendAnnual yield
| Institutions | 15.04% | 125.57M ADS | |
|---|---|---|---|
| 241 holders · as of Jun 30, 2026 | |||
| Insiders | 25.13% | 209.76M ADS | |
| 10 holders · as of Apr 10, 2026 | |||
| Other | 59.83% | 499.33M ADS | |
| remainder | |||
834.66M ADS as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
K. Satish Reddy1Insiderdirector | 13.58% | 113.36M ordinary | filed Sep 18, 2025 |
G. V. PrasadInsiderdirector | 11.51% | 96.10M ordinary | filed Mar 20, 2026 |
Robeco Institutional Asset Management B.V.Institution | 2.16% | 18.02M ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 1.31% | 10.94M ADS | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.27% | 10.59M ADS | as of Jun 30, 2026 |
- K. Satish Reddy's transaction reports restate only vehicles that traded; the 2025 ownership statement (113.36M) is used instead.
Insider tradesForm 4
Nothing filed in the last 12 months.
- Teva (ADR)
Broadest overlap in global, complex, and biosimilar medicines
- Viatris
Global rival across generics, established brands, and complex drugs
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories (ADR) | $12.57 | 0.00% | $10.33B | 29.8 | 33.5 | 3.0 | −15.5% |
| Teva (ADR) | $39.60 | +0.28% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Viatris | $17.15 | −0.17% | $19.91B | — | 6.7 | 1.4 | +4.9% |
| Median | 66.8 | 10.4 | 2.0 | +2.0% |